

- **Full Name:** Hee Kyung Ahn
  - **Current Position & Affiliation:** Associate Professor, Division of Medical Oncology, Gachon University Gil Medical Center
  - **Country:** Republic of Korea
- 

- **Educational Background:**

- MD, Sungkyunkwan University, School of Medicine, Seoul, Korea
- MS, Sungkyunkwan University, School of Medicine, Seoul, Korea

- **Professional Experience:**

- Associate professor, Division of Hematology and Oncology, Gachon University Gil Medical Center
- Assistant professor, Division of Hematology and Oncology, Gachon University Gil Medical Center
- Clinical assistant professor, Division of Hematology and Oncology, Gachon University Gil Medical Center
- Clinical fellow, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center
- Resident, Department of Medicine, Samsung Medical Center
- Intern, Samsung Medical Center, Seoul, Korea

- **Professional Organizations:**

- Member of Korean Society of Medical Oncology, Secretary of International affairs committee (May 2020-May 2024)
- Member of Korean Cancer Study Group, Secretary of Breast Cancer Committee (Sep 2019-Feb 2023)
- Member of Korean Breast Cancer Society, Chair of the 11<sup>th</sup> Korean Clinical Practice Guideline for Breast Cancer (Jun 2023-May2025)
- Member of Korean Association of Lung Cancer
- Member of Korean Society for Hospice and Palliative care
- Member of European Society of Medical Oncology
- Member of American Society of Clinical Oncology
- Member of International Association for the Study of Lung Cancer

**• Main Scientific Publications:**

1. **Ahn HK**, Sim SH, Suh KJ, Kim MH, Jeong JH, Kim JY, Lee DW, Ahn JH, Chae H, Lee KH, Kim JH, Lee KS, Sohn JH, Choi YL, Im SA, Jung KH, Park YH. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. *JAMA Oncol.* 2022 Sep 1;8(9):1271-1277. doi: 10.1001/jamaoncol.2022.2310.